<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953498</url>
  </required_header>
  <id_info>
    <org_study_id>AFSSAPS A70516-50</org_study_id>
    <nct_id>NCT00953498</nct_id>
  </id_info>
  <brief_title>Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins</brief_title>
  <official_title>Influence of Glitazones on the Vasodilatory Effect of HDL Lipoproteins and on Phospholipase A2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HDL from patients with type 2 diabetes show a significant reduction of their
      endothelium-dependent vasodilatory effect.

      The primary objective of the study is to analyze whether treatment with glitazones
      (pioglitazone and rosiglitazone)may improve the endothelium-dependent vasodilatory effect of
      HDL lipoproteins in patients with type 2 diabetes.

      The secondary objectives are:

        -  to analyze the effect of glitazone treatment on phospholipase A2

        -  to look for possible differences between the effects of pioglitazone and those of
           rosiglitazone

        -  to analyze the glycemic response to glitazone therapy according to clinical and
           biological baseline characteristics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed as follows:

      At baseline, before initiating glitazone treatment, clinical data will be recorded and blood
      samples will be obtained for biological measurements (blood glucose, HbA1c, total
      cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, liver enzymes), phospholipase
      A2 measurement and the study of the vasodilatory effect of HDL particles.For this purpose, we
      will study,using rabbit aorta rings,the ability of HDL to suppress the inhibition of
      vasodilation that is induced by oxidised LDL.

      For all the patients included into the study, a treatment by pioglitazone (at an initial dose
      of 30 mg/day) or rosiglitazone (at an initial dose of 4 mg/day) will be given by
      randomization.

      A visit will be performed at week 12, in order to titrate the glitazone dose (up to 45 mg/day
      for pioglitazone, up to 8 mg/day for rosiglitazone)according to HbA1c level and values of
      self-monitoring blood glucose.

      At week 24, the last visit will take place. During this visit, clinical data will be recorded
      and blood samples will be obtained for biological measurements (blood glucose, HbA1c, total
      cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol, liver enzymes), phospholipase
      A2 measurement and the study of the vasodilatory effect of HDL particles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Action of glitazone on the endothelium-dependent vasodilatory effects of HDL lipoproteins</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of glitazone therapy on Phospholipase A2 level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analyze the glycemic response to glitazones according to baseline clinical and biological characteristics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Look for possible differences between pioglitazone and rosiglitazone for their effects on HDL lipoproteins and phospholipase A2</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosiglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with rosiglitazone at a dose between 4mg and 8 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>After randomization, patients will be treated by pioglitazone or rosiglitazone</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>pioglitazone: ACTOS</other_name>
    <other_name>rosiglitazone: AVANDIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>treatment with rosiglitazone at a dose between 4mg and 8 mg/day</description>
    <arm_group_label>rosiglitazone</arm_group_label>
    <other_name>pioglitazone: ACTOS</other_name>
    <other_name>rosiglitazone: AVANDIA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with type 2 diabetes treated by oral antidiabetic agents (except glitazones)
             and/or insulin

          -  age&gt; 18 years

          -  HbA1c &gt; 6.5%

        Exclusion Criteria:

          -  renal failure

          -  heart failure

          -  primary hyperlipidemia

          -  pregnancy

          -  treatment that may modify lipid metabolism (glucocorticoids, oestrogens, retinoids,
             HIV antiviral drugs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno L Vergès, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dijon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service Endocrinologie-diabétologie, Hôpital du Bocage CHU</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Perségol L, Vergès B, Foissac M, Gambert P, Duvillard L. Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2006 Jun;49(6):1380-6. Epub 2006 Apr 5.</citation>
    <PMID>16596357</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <last_update_submitted>August 30, 2013</last_update_submitted>
  <last_update_submitted_qc>August 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Dijon</investigator_affiliation>
    <investigator_full_name>Prof. Bruno Vergès</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>glitazones</keyword>
  <keyword>HDL</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

